Evaluation of readmission in children receiving allogeneic hematopoietic stem cell transplantation: an institutional experience.
BACKGROUND
Use of unrelated cord blood (UCB) has become increasingly popular as a stem cell source, given the rapid availability and decreased potential of graft-versus-host disease. We sought to ascertain whether the use of UCB transplantation for pediatric patients changed the rates of unscheduled readmission.


METHODS
We analyzed the rate, causes, and evolution of hospitalization among patients receiving UCB versus matched sibling bone marrow. A retrospective analysis of the data from 54 patients who received a matched sibling hematopoietic stem cell transplantation (HSCT; n = 25; 46.3%) versus an unrelated cord blood transplantation (CBT; n = 29; 53.7%) was performed on subjects treated between 1998 and 2006. Patients who died before discharge (n = 4) were excluded from the readmission analysis.


RESULTS
A total of 50 patients were recruited for the analyses. Their median age was 6.7 years (range = 0.2-17 years). The median duration of hospitalization was 18 days shorter in the sibling HSCT group than in the unrelated CBT group. There were 89 readmissions in 25 patients (50%): 49 readmissions (55%) in the related HSCT and 40 (45%) in the unrelated CBT cohorts. Forty-two percent of readmissions were due to infections. Mortality following transplantation in 10 patients (19%) included sepsis (n = 3), intracranial hemorrhage (n = 1), pulmonary hemorrhage (n =1), and relapse (n = 5). Seven patients received HSCT from HLA-identical sibling donors and three from a cord blood donor.


CONCLUSIONS
For both groups, infection was the most common reason for readmission followed by graft failure and extramedullary relapse. Although the median hospital stay was shorter in the sibling donor group, some uncertainty exists as to whether the increased risk for readmission was related to proportionally more malignancies or to the severity of the illness. After HSCT, there was a frequent use of hospital resources: 46% of patients were hospitalized for a median of 11 days. The resulting health expenses seem to be useful, since 81% of subjects survived at 36-month follow-up.
Jaing
T-H
TH
Division of Hematology and Oncology, Department of Pediatrics, Chang Gung University, Taoyuan, Taiwan. jaing001@cgmh.org.tw
Tsay
P-K
PK
Yang
C-P
CP
Hung
I-J
IJ
Wen
Y-C
YC
Tseng
C-K
CK
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D006402:Hematologic Diseases / Q000401:mortality / Q000601:surgery; D019337:Hematologic Neoplasms / Q000401:mortality / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods*; D006801:Humans; D007223:Infant; D007902:Length of Stay; D010359:Patient Readmission / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D016019:Survival Analysis; D017741:Survivors; D014184:Transplantation, Homologous